Integrated analysis of dynamic FET PET/CT parameters, histology, and methylation profiling of 44 gliomas

PurposeDynamic 18F-FET PET/CT is a powerful tool for the diagnosis of gliomas.18F-FET PET time–activity curves (TAC) allow differentiation between histological low-grade gliomas (LGG) and high-grade gliomas (HGG). Molecular methods such as epigenetic profiling are of rising importance for glioma grading and subclassification. Here, we analysed dynamic 18F-FET PET data, and the histological and epigenetic features of 44 gliomas.MethodsDynamic 18F-FET PET was performed in 44 patients with newly diagnosed, untreated glioma: 10 WHO grade II glioma, 13 WHO grade III glioma and 21 glioblastoma (GBM). All patients underwent stereotactic biopsy or tumour resection after 18F-FET PET imaging. As well as histological analysis of tissue samples, DNA was subjected to epigenetic analysis using the Illumina 850 K methylation array. TACs, standardized uptake values corrected for background uptake in healthy tissue (SUVmax/BG), time to peak (TTP) and kinetic modelling parameters were correlated with histological diagnoses and with epigenetic signatures. Multivariate analyses were performed to evaluate the diagnostic accuracy of 18F-FET PET in relation to the tumour groups identified by histological and methylation-based analysis.ResultsEpigenetic profiling led to substantial tumour reclassification, with six grade II/III gliomas reclassified as GBM. Overlap of HGG-typical TACs and LGG-typical TACs was dramatically reduced when tumours were clustered on the basis of their methylation profile. SUVmax/BG values of GBM were higher than those of LGGs following both histological diagnosis and methylation-based diagnosis. The differences in TTP between GBMs and grade II/III gliomas were greater following methylation-based diagnosis than following histological diagnosis. Kinetic modeling showed that relative K1 and fractal dimension (FD) values significantly differed in histology- and methylation-based GBM and grade II/III glioma between those diagnosed histologically and those diagnosed by methylation analysis. Multivariate analysis revealed slightly greater diagnostic accuracy with methylation-based diagnosis. IDH-mutant gliomas and GBM subgroups tended to differ in their 18F-FET PET kinetics.ConclusionThe status of dynamic 18F-FET PET as a biologically and clinically relevant imaging modality is confirmed in the context of molecular glioma diagnosis.

[1]  K. Hamacher,et al.  O-(2-[18F]fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  Karl-Josef Langen,et al.  O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. , 2005, Brain : a journal of neurology.

[3]  Jochen Herms,et al.  FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[5]  C. Boy,et al.  The quantification of dynamic FET PET imaging and correlation with the clinical outcome in patients with glioblastoma , 2009, Physics in medicine and biology.

[6]  Xavier Robin,et al.  pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.

[7]  Peter Dalgaard,et al.  R Development Core Team (2010): R: A language and environment for statistical computing , 2010 .

[8]  R. Baum,et al.  Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine (F-18 FET) PET for Glioma Grading: Assessment of Individual Probability of Malignancy , 2011, Clinical nuclear medicine.

[9]  A. von Deimling,et al.  Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. , 2011, Neuro-oncology.

[10]  Kirsten Schmieder,et al.  Pharmacokinetic Studies of 68Ga-Labeled Bombesin (68Ga-BZH3) and F-18 FDG PET in Patients With Recurrent Gliomas and Comparison to Grading: Preliminary Results , 2011, Clinical nuclear medicine.

[11]  J. Tonn,et al.  MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET? , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  Paul Cumming,et al.  Prediction of oligodendroglial histology and LOH 1p/19q using dynamic [(18)F]FET-PET imaging in intracranial WHO grade II and III gliomas. , 2012, Neuro-oncology.

[13]  David T. W. Jones,et al.  Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. , 2012, Cancer cell.

[14]  Matthew J. Betts,et al.  Dissecting the genomic complexity underlying medulloblastoma , 2012, Nature.

[15]  Thomas Beez,et al.  Diagnostic Performance of 18F-FET PET in Newly Diagnosed Cerebral Lesions Suggestive of Glioma , 2013, The Journal of Nuclear Medicine.

[16]  Gereon R Fink,et al.  Role of O-(2-18F-Fluoroethyl)-l-Tyrosine PET as a Diagnostic Tool for Detection of Malignant Progression in Patients with Low-Grade Glioma , 2013, The Journal of Nuclear Medicine.

[17]  Martin Sill,et al.  Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma , 2014, Acta Neuropathologica.

[18]  David T. W. Jones,et al.  ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma , 2014, Acta Neuropathologica.

[19]  Uwe Haberkorn,et al.  Intra-individual comparison of ¹⁸F-FET and ¹⁸F-DOPA in PET imaging of recurrent brain tumors. , 2014, Neuro-oncology.

[20]  P. Bartenstein,et al.  Dynamic 18F-FET PET in Newly Diagnosed Astrocytic Low-Grade Glioma Identifies High-Risk Patients , 2014, The Journal of Nuclear Medicine.

[21]  U. Haberkorn,et al.  Intra-individual comparison of 18 F-FET and 18 F-DOPA in PET imaging of recurrent brain tumors , 2014 .

[22]  N. Galldiks,et al.  From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors? , 2015, Neuro-oncology.

[23]  N. Albert,et al.  Early static 18F-FET-PET scans have a higher accuracy for glioma grading than the standard 20–40 min scans , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  Pieter Wesseling,et al.  IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO , 2015, Acta Neuropathologica.

[25]  Stefan Förster,et al.  Textural analysis of pre-therapeutic [18F]-FET-PET and its correlation with tumor grade and patient survival in high-grade gliomas , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[26]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[27]  Ian Law,et al.  Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. , 2016, Neuro-oncology.

[28]  John O. Prior,et al.  Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis. , 2016, Neuro-oncology.

[29]  G. Reifenberger,et al.  Advances in the molecular genetics of gliomas — implications for classification and therapy , 2017, Nature Reviews Clinical Oncology.

[30]  Gereon R Fink,et al.  Static and dynamic 18F–FET PET for the characterization of gliomas defined by IDH and 1p/19q status , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[31]  F. Mottaghy,et al.  Imaging of amino acid transport in brain tumours: Positron emission tomography with O-(2-[18F]fluoroethyl)-L-tyrosine (FET). , 2017, Methods.

[32]  Martin Sill,et al.  DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. , 2017, The Lancet. Oncology.

[33]  N. Samadi,et al.  Comparison of genome‐wide analysis techniques to DNA methylation analysis in human cancer , 2018, Journal of cellular physiology.

[34]  Armin Giese,et al.  Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma , 2018, Neuro-oncology.

[35]  David T. W. Jones,et al.  Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis , 2018, Brain pathology.

[36]  M. Hegi,et al.  Glioma epigenetics: From subclassification to novel treatment options. , 2017, Seminars in cancer biology.